The "Oral Thin Films Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.

The global oral thin films market is experiencing a dynamic upsurge, expected to grow significantly to $7.65 billion by 2028, advancing at a compound annual growth rate (CAGR) of 13.6%. This remarkable growth trajectory is underpinned by the versatile and patient-friendly nature of oral thin films, which is greatly influencing their adoption across a diverse range of therapeutic areas. Innovation at the Forefront:

Strategic innovations by leading market participants are propelling the oral thin films industry forward. Recent product launches and approvals signify the market's commitment to addressing patient-specific needs, especially for those suffering from conditions such as migraines and schizophrenia. Oral thin films are becoming increasingly favored due to their ease of administration and rapid onset of action, which are pivotal for chronic conditions requiring consistent and effective medication management.

Market Drivers:

The augmenting demand for rapid-acting and convenient delivery systems, alongside the rise in specialty pharmaceuticals, precision medicine, and oral vaccines, are key drivers in this market's growth. The global rise in mental health medication requirements continues to contribute substantially to the escalating demand for oral thin films, with such platforms offering considerable improvements in dosage precision and patient adherence.

Strategic Acquisitions:

Recent strategic acquisitions within the industry not only reflect the market's robustness but are also enhancing the capabilities of key players, allowing for greater innovation and expansion in oral thin film technologies. These developments are indicative of the ongoing emphasis on versatility and patient-centered approaches in drug delivery systems.

Regional Insights:

North America leads the oral thin films market due to advanced healthcare infrastructure and a pronounced focus on research and development. However, Asia-Pacific is projected to witness the fastest growth, thanks to increasing healthcare expenditures and heightened awareness of novel drug delivery systems among burgeoning populations. The oral thin films market reflects the commitment to innovation and patient care, with leading companies continually seeking to expand therapeutic applications and improve drug delivery mechanisms. This sector's growth signals a transformative era in pharmaceuticals, where convenience and efficacy are paramount.

A selection of companies mentioned in this report includes, but is not limited to:

• ZIM Laboratories Limited
• NAL Pharma
• Cure Pharmaceutical Holding Corp.
• IntelGenx Corp.
• Kyu Kyu Pharmaceutical Co. Ltd.
• Sunovion Pharmaceuticals Inc.
• Seoul Pharma Co. Ltd.
• Aquestive Therapeutics Inc.
• Shilpa Therapeutics Pvt. Ltd.
• Mylan Inc.
• LIVKON Pharmaceuticals Pvt. Ltd.
• Panacea Biotec Ltd.
• Adare Pharmaceuticals Inc.
• APR Applied Pharma Research SA
• BioDelivery Sciences International Inc.
• Sumitomo Dainippon Pharma Co. Ltd.
• Indivior PLC
• LTS Lohmann Therapie-Systeme AG
• Tesa Labtec GmbH
• Pfizer Inc.
• Sanofi S.A.
• Merck & Co. Inc.
• Novartis International AG
• Roche Holding AG
• Johnson & Johnson
• GlaxoSmithKline plc
• Bayer AG
• Eli Lilly and Company
• AbbVie Inc.
• Bristol-Myers Squibb Company
• Novo Nordisk A/S
• AstraZeneca plc

For more information about this report visit https://www.researchandmarkets.com/r/vo1110

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240425982908/en/